-
1.发明申请
公开(公告)号：WO2009143429A3
公开(公告)日：2010-01-07
申请号：PCT/US2009044986
申请日：2009-05-22
Applicant: BAXTER INT , BAXTER HEALTHCARE SA , MITTERMAYR RAINER , HELGERSON SAM L , REDL HEINZ
Inventor： MITTERMAYR RAINER , HELGERSON SAM L , REDL HEINZ
CPC classification number: A61K38/363 , A61K38/1858 , A61K38/4833 , A61K2300/00
Abstract: The present application demonstrates the clinical potential of fibrin sealants to locally deliver growth factors to ischemic tissue. More particularly, it demonstrates that hydrogels such as Fibrin Sealants can be used to deliver VEGF165 to prevent tissue necrosis caused by hypoxia or ischemia. Specifically, a Fibrin Sealant (FS) was used to deliver VEGF165 to treat tissue necrosis in both a rodent dorsal flap model and a rodent epigastric flap model. Flaps treated with FS spiked with (rh)VEGF165 developed less necrotic tissue. In addition, immunohistological studies revealed a greater numbers of blood vessels (angiogenesis).
Abstract translation: 本申请表明纤维蛋白封闭剂局部递送生长因子到缺血组织的临床潜力。 更具体地说，它表明水凝胶如纤维蛋白密封剂可用于递送VEGF165以防止由缺氧或局部缺血引起的组织坏死。 具体来说，纤维蛋白密封剂（FS）用于递送VEGF165以在啮齿动物背侧皮瓣模型和啮齿动物上腹膜模型中治疗组织坏死。 用（rh）VEGF165掺入的FS处理的皮瓣发育较少的坏死组织。 此外，免疫组织化学研究显示出更多的血管（血管生成）。
-
2.发明申请
公开(公告)号：WO2008089466A3
公开(公告)日：2009-11-26
申请号：PCT/US2008051528
申请日：2008-01-18
Applicant: BAXTER INT , BAXTER HEALTHCARE SA , CATELAS ISABELLE , HELGERSON SAM L
Inventor： CATELAS ISABELLE , HELGERSON SAM L
CPC classification number: A61K38/1841 , A61K9/0024
Abstract: The present invention relates, in general, to fibrin sealants, which contain transforming growth factor-beta (TGF- ß) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, such as bone and cartilage disorders, soft tissue disorders and cardiovascular diseases.
Abstract translation: 本发明一般涉及纤维蛋白封闭剂，其含有转移生长因子-β（TGF-β）用于治疗应用的原位控释，包括骨骼和软骨疾病，软组织疾病和心血管疾病等肌肉骨骼疾病 。
-
公开(公告)号：WO0226779A3
公开(公告)日：2003-08-14
申请号：PCT/US0129933
申请日：2001-09-25
Applicant: BAXTER AG , BAXTER INT
Inventor： REDL HEINZ , FURST WALTER , KNEIDINGER RUDOLF , HELGERSON SAM L , LOOKER DOUGLAS L , INMAN ELISABETH M , RICHARDS JANE P , WONG CATALINA
IPC: A61K47/42 , A61K38/00 , A61K47/48 , C07K14/475 , C07K14/50 , C07K14/705 , C07K14/745 , C07K14/75 , C07K14/78 , C07K16/00 , C07K19/00 , C12N15/12 , C12N15/62 , A61K38/17 , A61K38/48 , C07K14/19 , C12N9/74 , C12N15/52
CPC classification number: C07K14/745 , A61K38/00 , A61K47/64 , A61K47/6435 , A61K47/665 , B82Y5/00
Abstract: A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substacne from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF185 C-terminal domain fused to a wound-healing substance such as leptin.
Abstract translation: 一种纤维蛋白/纤维蛋白原结合缀合物，用于形成用于从血纤维蛋白凝块中持续释放药物活性成分的贮库。 缀合物包含直接或通过介入物质捕获部分如抗体与药物活性物质结合的纤维蛋白/纤维蛋白原结合部分。 缀合物还可以是包含纤维蛋白/纤维蛋白原结合部分的重组融合蛋白，例如融合到伤口愈合物质如瘦蛋白的VEGF185 C-末端结构域。
-
公开(公告)号：WO2008157733A3
公开(公告)日：2009-11-12
申请号：PCT/US2008067562
申请日：2008-06-19
Applicant: BAXTER INT , BAXTER HEALTHCARE SA , CATELAS ISABELLE , DWYER JOSEPH , SEYTON WANDA , DONOVAN SHANE , HELGERSON SAM L
Inventor： CATELAS ISABELLE , DWYER JOSEPH , SEYTON WANDA , DONOVAN SHANE , HELGERSON SAM L
CPC classification number: A61K38/1858 , A61L24/0015 , A61L24/106 , A61L2300/414
Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
Abstract translation: 本发明一般涉及含有血小板衍生生长因子（PDGF）的纤维蛋白封闭剂，用于治疗应用的包括肌肉骨骼疾病，软组织疾病和血管疾病在内的控制释放。
-
公开(公告)号：BRPI0812718A2
公开(公告)日：2014-12-23
申请号：BRPI0812718
申请日：2008-06-19
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： CATELAS ISABELLE , DWYER JOSEPH , SEYTON WANDA , DONOVAN SHANE , HELGERSON SAM L
Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
-
Patent Agency Ranking
公开(公告)号：CA2192455C
公开(公告)日：2007-11-20
申请号：CA2192455
申请日：1995-06-13
Applicant: BAXTER INT
Inventor： TSENG-LAW JANET , KOBORI JOAN A , AL-ABDALY FAHAD A , GUILLERMO ROY , HELGERSON SAM L , DEANS ROBERT J
IPC: C07K16/00 , G01N33/53 , C07K1/04 , C07K5/113 , C07K7/06 , C07K7/08 , C07K7/64 , C07K14/00 , C07K14/705 , C07K16/28 , C07K16/30 , C12N1/02 , C12N5/00 , C12N5/06 , C12N5/08 , C12N5/12 , C12N15/00 , C12N15/09 , C12P21/08 , C12R1/91 , G01N33/543 , G01N33/554 , G01N33/566 , G01N33/569 , G01N33/577
Abstract: The invention provides a non-enzymatic method for the release of cells which have beem positively selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support . The method entails forming within the cell suspension a complex comprising the solid support linked to a primary monoclonal antibody , which in tum is bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen. The invention also provides methods for identifying a specific peptide useful for the release of a target cell from the binding of a specific monoclonal antibody. The methods of the invention are particularly useful for the positive selection of CD34+ hematopoietic stem cells and the concomitant purging of undesired tumor cells or lymphocytes from the positively selected cell population. The purified CD34+ cell composition is then usefulfor reinfusion to a cancer patient after high-dose therapy in order to reconstitute the patient's immune system.
-
公开(公告)号：AT169409T
公开(公告)日：1998-08-15
申请号：AT95923835
申请日：1995-06-13
Applicant: BAXTER INT
Inventor： TSENG-LAW JANET , KOBORI JOAN A , AL-ABDALY FAHAD A , GUILLERMO ROY , HELGERSON SAM L , DEANS ROBERT J
IPC: G01N33/53 , C07K1/04 , C07K5/113 , C07K7/06 , C07K7/08 , C07K7/64 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/00 , C12N5/06 , C12N15/00 , C12N15/09 , C12P21/08 , C12R1/91 , G01N33/569 , G01N33/577 , C07K14/52
Abstract: The invention provides a nonenzymic method for the release of cells which have been selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary monoclonal antibody, which in turn is bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen.
-
公开(公告)号：BRPI0806622A2
公开(公告)日：2011-09-13
申请号：BRPI0806622
申请日：2008-01-18
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： CATELAS ISABELLE , HELGERSON SAM L
Abstract: The present invention relates, in general, to fibrin sealants, which contain transforming growth factor-beta (TGF-beta) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, such as bone and cartilage disorders, soft tissue disorders and cardiovascular diseases.
-
公开(公告)号：DE60138965D1
公开(公告)日：2009-07-23
申请号：DE60138965
申请日：2001-09-25
Applicant: BAXTER INNOVATIONS GMBH , BAXTER INT
Inventor： REDL HEINZ , FUERST WALTER , KNEIDINGER RUDOLF , HELGERSON SAM L , LOOKER DOUGLAS L , INMAN ELISABETH M , RICHARDS JANE P , WONG CATALINA
-
公开(公告)号：CA2675157A1
公开(公告)日：2008-07-24
申请号：CA2675157
申请日：2008-01-18
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： CATELAS ISABELLE , HELGERSON SAM L
Abstract: The present invention relates, in general, to fibrin sealants, which cont ain transforming growth factor-beta (TGF- .beta.) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, such as bone and cartilage disorders, soft tissue disorders and cardiovascular d iseases.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.02 seconds)
